Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Eligibility

Inclusion Criteria:

* 18 years old or older
* Unresectable, metastatic or locally advanced ALK-positive NSCLC.
* Must have received lorlatinib as first or second line TKI
* One prior line of systemic chemotherapy is permitted
* Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose

Exclusion Criteria:

* Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression
* Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)

Conditions6

Interventions2

Locations1 site

Find trials near these locations

Related trials

• A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib — Centro di Riferimento Oncologico - Aviano
• AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer — Chugai Pharmaceutical
• Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context — Pfizer
• Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients — Sichuan Cancer Hospital and Research Institute
• The Drug Rediscovery Protocol (DRUP Trial) — The Netherlands Cancer Institute
• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) — Children's Oncology Group
• Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion — Nationwide Children's Hospital
• Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer — M.D. Anderson Cancer Center

Browse More Trials